Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto

Size: px
Start display at page:

Download "Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto"

Transcription

1 Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy issues. Compare Lovenox vs. Xarelto, which is better for uses like: Blood Clots, DVT and DVT Prophylaxis. Compare head-to-head ratings, side effects, warnings, dosages. Lovenox (Enoxaparin) is a good anticoagulant that reduces the risk of death or bleeding, and blood clots are less likely to happen. However, it is only available as Lovenox - Prescribed for Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Acute Coronary Syndrome, Deep Vein Thrombosis How to Convert Between Anticoagulants.. Xarelto package insert Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non. Compare Lovenox vs. Xarelto, which is better for uses like: Blood Clots, DVT and DVT Prophylaxis. Compare head-to-head ratings, side effects, warnings, dosages Detailed dosage guidelines and administration information for Xarelto (rivaroxaban). Includes dose adjustments, warnings and precautions. Xarelto (rivaroxaban) is a good medication for preventing blood clots. It doesn't require regular blood tests or changing doses often. However, it can be expensive and there's no way to reverse the medication's effects. Lovenox ( Enoxaparin) is a good anticoagulant that reduces the risk of death or bleeding, and blood clots. CONVERSION, RECOMMENDATION. warfarin to rivaroxaban. Stop warfarin and start rivaroxaban when INR < 2. (manufacturer recommends stop warfarin and start rivaroxaban when INR < 3). rivaroxaban to warfarin. (NOTE: rivaroxaban is not intended to be used as a short term "bridge" to warfarin. Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, Edoxaban (Savaysa) Package Insert. Product Information: SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi Sankyo, Inc., Parsippany, NJ, Rivaroxaban (Xarelto) Package Insert. Product Information: XARELTO(R) oral tablets, rivaroxaban oral

2 tablets. Jan 25, Xarelto package insert. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurology. 2012;11: Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Lovenox - Prescribed for Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Acute Coronary Syndrome, Deep Vein Thrombosis - Prophylaxis, Angina, Deep Vein Thrombosis Prophylaxis. Xarelto limits the ability of the blood to clot and is effective at treating or preventing conditions where. Helpful resources for healthcare professionals who are prescribing XARELTO. See Important Safety Info & full Prescribing Info, including Boxed WARNINGS. Jan 6, Rivaroxaban (Xarelto) A randomized open-label study (EINSTEIN) in 3449 patients compared rivaroxaban alone to standard therapy with the LMWH enoxaparin (Lovenox, and generics) plus a vitamin K antagonist for treatment of acute VTE. Rivaroxaban was non-inferior to standard therapy in reducing. rivaroxaban. If CrCl <30 ml/min, wait 24 hours after last dose of dabigatran to initiate apixaban or rivaroxaban. Brand. Generic. Arixtra fondaparinux. Coumadin warfarin. Eliquis apixaban. Fragmin dalteparin. Lovenox enoxaparin. Pradaxa dabigatran. Xarelto rivaroxaban. Abbreviations: INR = international normalized ratio. Dec 29, Xarelto (rivaroxaban) received a new FDA indication for deep venous thrombosis and pulmonary embolism (DVT and PE) in November Xarelto's new indication. Find a comprehensive guide to possible side effects including common and rare side effects when taking Xarelto (Rivaroxaban Film-Coated Oral Tablets) for healthcare professionals and consumers. Nasenbluten bei xarelto; Erfahrungsberichte: 14 (6%); xarelto, auch xarelto, Xarelto 20, Xarelto Filmtabletten, xarelto: Zahn ziehen, XARELTO 1%. Xarelto (rivaroxaban) is used for the prevention of deep vein thrombosis (DVT) in people undergoing knee or hip replacement surgery. Includes Xarelto side effects, interactions and indications. Conversion Table for Oral Anticoagulants in A-Fib (updated 5/6/2013) SWITCH.. Xarelto (rivaroxaban) Pradaxa (dabigatran) Eliquis (apixaban) From Warfarin D/C warfarin and start Xarelto once Ontario Limited Use Code lookup with your browser for all platforms. You can save the page for offline use as well. I decided to start researching some of the more recent supplements I've added to my program to see if any of them interact with Xarelto, since I just spent yesterday in the ER with stroke

3 symptoms. Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs. Learn about side effects, interactions and indications. When ibritumomab, pentoxifylline, or certain blood thinners are taken with Lovenox, drug interactions may occur. These interactions can increase the risk of bleeding, including dangerous internal bleeding. XARELTO 10 mg cp pellic : Synthèse, Formes et présentations, Composition, Indications, Posologie et mode d'administration, Contre-indications, Mises en garde et précautions d'emploi, Interactions, Fertilité / grossesse / allaitement, Conduite et utilisation de machines, Effets indésirables, Surdosage, Pharmacodynamie, Pharmacocinétique. Find a comprehensive guide to possible side effects including common and rare side effects when taking Lovenox (Enoxaparin Sodium Injection) for healthcare professionals and consumers. Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy issues. Compare Lovenox vs. Xarelto, which is better for uses like: Blood Clots, DVT and DVT Prophylaxis. Compare head-to-head ratings, side effects, warnings, dosages How to Convert Between Anticoagulants.. Xarelto package insert Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non. Lovenox (Enoxaparin) is a good anticoagulant that reduces the risk of death or bleeding, and blood clots are less likely to happen. However, it is only available as Detailed dosage guidelines and administration information for Xarelto (rivaroxaban). Includes dose adjustments, warnings and precautions Lovenox - Prescribed for Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Acute Coronary Syndrome, Deep Vein Thrombosis. Compare Lovenox vs. Xarelto, which is better for uses like: Blood Clots, DVT and DVT Prophylaxis. Compare head-to-head ratings, side effects, warnings, dosages. Xarelto (rivaroxaban) is a good medication for preventing blood clots. It doesn't require regular blood tests or changing doses often. However, it can be expensive and there's no way to reverse the medication's effects. Lovenox ( Enoxaparin) is a good anticoagulant that reduces the risk of death or bleeding, and blood clots. rivaroxaban. If CrCl <30 ml/min, wait 24 hours after last dose of dabigatran to initiate apixaban or rivaroxaban. Brand. Generic. Arixtra fondaparinux. Coumadin warfarin. Eliquis apixaban. Fragmin dalteparin. Lovenox enoxaparin. Pradaxa dabigatran. Xarelto

4 rivaroxaban. Abbreviations: INR = international normalized ratio. Dec 29, Xarelto (rivaroxaban) received a new FDA indication for deep venous thrombosis and pulmonary embolism (DVT and PE) in November Xarelto's new indication. Lovenox - Prescribed for Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Acute Coronary Syndrome, Deep Vein Thrombosis - Prophylaxis, Angina, Deep Vein Thrombosis Prophylaxis. Xarelto limits the ability of the blood to clot and is effective at treating or preventing conditions where. Jan 6, Rivaroxaban (Xarelto) A randomized open-label study (EINSTEIN) in 3449 patients compared rivaroxaban alone to standard therapy with the LMWH enoxaparin (Lovenox, and generics) plus a vitamin K antagonist for treatment of acute VTE. Rivaroxaban was non-inferior to standard therapy in reducing. Helpful resources for healthcare professionals who are prescribing XARELTO. See Important Safety Info & full Prescribing Info, including Boxed WARNINGS. Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, Edoxaban (Savaysa) Package Insert. Product Information: SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi Sankyo, Inc., Parsippany, NJ, Rivaroxaban (Xarelto) Package Insert. Product Information: XARELTO(R) oral tablets, rivaroxaban oral tablets. CONVERSION, RECOMMENDATION. warfarin to rivaroxaban. Stop warfarin and start rivaroxaban when INR < 2. (manufacturer recommends stop warfarin and start rivaroxaban when INR < 3). rivaroxaban to warfarin. (NOTE: rivaroxaban is not intended to be used as a short term "bridge" to warfarin. Jan 25, Xarelto package insert. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in nonvalvular atrial fibrillation. Lancet Neurology. 2012;11: Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Xarelto (rivaroxaban) is used for the prevention of deep vein thrombosis (DVT) in people undergoing knee or hip replacement surgery. Includes Xarelto side effects, interactions and indications. When ibritumomab, pentoxifylline, or certain blood thinners are taken with Lovenox, drug interactions may occur. These interactions can increase the risk of bleeding, including dangerous internal bleeding. Find a comprehensive guide to possible side effects including common and rare side effects when taking Lovenox (Enoxaparin Sodium Injection) for healthcare professionals and consumers. Find a comprehensive guide to possible side effects

5 including common and rare side effects when taking Xarelto (Rivaroxaban Film-Coated Oral Tablets) for healthcare professionals and consumers. Ontario Limited Use Code lookup with your browser for all platforms. You can save the page for offline use as well. Nasenbluten bei xarelto; Erfahrungsberichte: 14 (6%); xarelto, auch xarelto, Xarelto 20, Xarelto Filmtabletten, xarelto: Zahn ziehen, XARELTO 1%. Conversion Table for Oral Anticoagulants in A-Fib (updated 5/6/2013) SWITCH.. Xarelto (rivaroxaban) Pradaxa (dabigatran) Eliquis (apixaban) From Warfarin D/C warfarin and start Xarelto once XARELTO 10 mg cp pellic : Synthèse, Formes et présentations, Composition, Indications, Posologie et mode d'administration, Contre-indications, Mises en garde et précautions d'emploi, Interactions, Fertilité / grossesse / allaitement, Conduite et utilisation de machines, Effets indésirables, Surdosage, Pharmacodynamie, Pharmacocinétique. I decided to start researching some of the more recent supplements I've added to my program to see if any of them interact with Xarelto, since I just spent yesterday in the ER with stroke symptoms. Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs. Learn about side effects, interactions and indications Detailed dosage guidelines and administration information for Xarelto (rivaroxaban). Includes dose adjustments, warnings and precautions. Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy issues. Lovenox (Enoxaparin) is a good anticoagulant that reduces the risk of death or bleeding, and blood clots are less likely to happen. However, it is only available as. Compare Lovenox vs. Xarelto, which is better for uses like: Blood Clots, DVT and DVT Prophylaxis. Compare head-to-head ratings, side effects, warnings, dosages Lovenox - Prescribed for Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Acute Coronary Syndrome, Deep Vein Thrombosis How to Convert Between Anticoagulants.. Xarelto package insert Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non. Compare Lovenox vs. Xarelto, which is better for uses like: Blood Clots, DVT and DVT Prophylaxis. Compare head-to-head ratings, side effects, warnings, dosages. Jan 25, Xarelto package insert. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurology. 2012;11: Schulman S, Crowther MA.

6 How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Jan 6, Rivaroxaban (Xarelto) A randomized open-label study (EINSTEIN) in 3449 patients compared rivaroxaban alone to standard therapy with the LMWH enoxaparin (Lovenox, and generics) plus a vitamin K antagonist for treatment of acute VTE. Rivaroxaban was non-inferior to standard therapy in reducing. Dec 29, Xarelto (rivaroxaban) received a new FDA indication for deep venous thrombosis and pulmonary embolism (DVT and PE) in November Xarelto's new indication. Helpful resources for healthcare professionals who are prescribing XARELTO. See Important Safety Info & full Prescribing Info, including Boxed WARNINGS. Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, Edoxaban (Savaysa) Package Insert. Product Information: SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi Sankyo, Inc., Parsippany, NJ, Rivaroxaban (Xarelto) Package Insert. Product Information: XARELTO(R) oral tablets, rivaroxaban oral tablets. CONVERSION, RECOMMENDATION. warfarin to rivaroxaban. Stop warfarin and start rivaroxaban when INR < 2. (manufacturer recommends stop warfarin and start rivaroxaban when INR < 3). rivaroxaban to warfarin. (NOTE: rivaroxaban is not intended to be used as a short term "bridge" to warfarin. rivaroxaban. If CrCl <30 ml/min, wait 24 hours after last dose of dabigatran to initiate apixaban or rivaroxaban. Brand. Generic. Arixtra fondaparinux. Coumadin warfarin. Eliquis apixaban. Fragmin dalteparin. Lovenox enoxaparin. Pradaxa dabigatran. Xarelto rivaroxaban. Abbreviations: INR = international normalized ratio. Lovenox - Prescribed for Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Acute Coronary Syndrome, Deep Vein Thrombosis - Prophylaxis, Angina, Deep Vein Thrombosis Prophylaxis. Xarelto limits the ability of the blood to clot and is effective at treating or preventing conditions where. Xarelto (rivaroxaban) is a good medication for preventing blood clots. It doesn't require regular blood tests or changing doses often. However, it can be expensive and there's no way to reverse the medication's effects. Lovenox ( Enoxaparin) is a good anticoagulant that reduces the risk of death or bleeding, and blood clots. Find a comprehensive guide to possible side effects including common and rare side effects when taking Lovenox (Enoxaparin Sodium Injection) for healthcare professionals and consumers. XARELTO 10 mg cp pellic : Synthèse, Formes et

7 présentations, Composition, Indications, Posologie et mode d'administration, Contre-indications, Mises en garde et précautions d'emploi, Interactions, Fertilité / grossesse / allaitement, Conduite et utilisation de machines, Effets indésirables, Surdosage, Pharmacodynamie, Pharmacocinétique. I decided to start researching some of the more recent supplements I've added to my program to see if any of them interact with Xarelto, since I just spent yesterday in the ER with stroke symptoms. Nasenbluten bei xarelto; Erfahrungsberichte: 14 (6%); xarelto, auch xarelto, Xarelto 20, Xarelto Filmtabletten, xarelto: Zahn ziehen, XARELTO 1%. Xarelto (rivaroxaban) is used for the prevention of deep vein thrombosis (DVT) in people undergoing knee or hip replacement surgery. Includes Xarelto side effects, interactions and indications. Ontario Limited Use Code lookup with your browser for all platforms. You can save the page for offline use as well. Conversion Table for Oral Anticoagulants in A-Fib (updated 5/6/2013) SWITCH.. Xarelto (rivaroxaban) Pradaxa (dabigatran) Eliquis (apixaban) From Warfarin D/C warfarin and start Xarelto once When ibritumomab, pentoxifylline, or certain blood thinners are taken with Lovenox, drug interactions may occur. These interactions can increase the risk of bleeding, including dangerous internal bleeding. Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs. Learn about side effects, interactions and indications. Find a comprehensive guide to possible side effects including common and rare side effects when taking Xarelto (Rivaroxaban Film-Coated Oral Tablets) for healthcare professionals and consumers. Contact Information Telephone or BORG (2674) FAX Postal address Minnetonka Industrial Rd. Minnetonka, MN Electronic mail General Information: Icd 10 prforated prepyloric ulcer Menage a twins episode 1 english dub

8 Sitemap Thursday, July 29, 1999 This Site Has Been Visited Times.

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),

More information

Oral Anticoagulation Drug Class Prior Authorization Protocol

Oral Anticoagulation Drug Class Prior Authorization Protocol Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),

More information

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe

More information

Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017

Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017 Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts

More information

Change from lovenox to pradaxa

Change from lovenox to pradaxa P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary

More information

Xarelto (rivaroxaban)

Xarelto (rivaroxaban) Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto

More information

Drug Use Criteria: Direct Oral Anticoagulants

Drug Use Criteria: Direct Oral Anticoagulants Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed

More information

UW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT

UW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT UW MEDICINE PATIENT EDUCATION Treating Blood Clots About deep vein thrombosis (DVT) and pulmonary embolism (PE) and how they are treated This handout explains blood clots, their symptoms, and how they

More information

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date: Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18

Clinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18 Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

to a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching

to a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services } Identify the FDA approved direct oral anticoagulants (DOACs) } Distinguish the differences in the dosing of DOACs for various indications

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT

QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-237-L01-T 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for

More information

What s new with DOACs? Defining place in therapy for edoxaban &

What s new with DOACs? Defining place in therapy for edoxaban & What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas

More information

SAVAYSA (edoxaban tosylate) oral tablet

SAVAYSA (edoxaban tosylate) oral tablet SAVAYSA (edoxaban tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Pradaxa (dabigatran)

Pradaxa (dabigatran) Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa

More information

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

Eliquis effect on inr prolongation 2017

Eliquis effect on inr prolongation 2017 Eliquis effect on inr prolongation 2017 The Borg System is 100 % Eliquis effect on inr prolongation 2017 Dec 17, 2016. Clin Chem Lab Med 2017; 55(8): e178 e180. Letter to the Editor. Tuukka A. Helin. prolongs

More information

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from

More information

Plavix eliquis and aspirin

Plavix eliquis and aspirin Plavix eliquis and aspirin The Borg System is 100 % Plavix eliquis and aspirin 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ). Eliquis

More information

Title: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)

Title: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra) Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.

More information

Drug Class Review Newer Oral Anticoagulant Drugs

Drug Class Review Newer Oral Anticoagulant Drugs Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

About Blood Clots and How to Treat Them

About Blood Clots and How to Treat Them PATIENT & CAREGIVER EDUCATION About Blood Clots and How to Treat Them This information describes what a blood clot is and how it is treated. About Blood Clots When you have a cut or an injury, your blood

More information

NEWSLETTER DUE CARE PROGRAM. WINTER 2014 Summer 2015 COMMONLY ASKED QUESTION:

NEWSLETTER DUE CARE PROGRAM. WINTER 2014 Summer 2015 COMMONLY ASKED QUESTION: DUE CARE PROGRAM NEWSLETTER WINTER 2014 Summer 2015 Lisa Sather, RPh DUR Coordinator Mountain-Pacific Quality Health 3404 Cooney Drive Helena, MT 59602 406-457-5818 The DUE CARE PROGRAM, administered by

More information

Anticoagulation: Novel Agents

Anticoagulation: Novel Agents Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical

More information

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

Comparison of novel oral anticoagulants (NOACs)

Comparison of novel oral anticoagulants (NOACs) Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic

More information

NOAC s across indications

NOAC s across indications Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich

More information

New Anticoagulants Therapies

New Anticoagulants Therapies New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation

More information

The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives

The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List

More information

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

Professional Practice Minutes December 7, 2016

Professional Practice Minutes December 7, 2016 Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon

More information

Aspirin versus pradaxa

Aspirin versus pradaxa Search Search Aspirin versus pradaxa 14-12-2012 Dabigatran (Pradaxa): Good news on safety but caution still warranted. the risk of bleeding versus the risk. (Aspirin and other inhibitors of. 15-12-2008

More information

Abstract. Background. Methods

Abstract. Background. Methods Abstract Background Malignancy is a major risk factor for developing venous thromboembolism (VTE), and thus cancer patients are at high risk for deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

More information

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support

More information

Updates in Management of Venous Thromboembolic Disease

Updates in Management of Venous Thromboembolic Disease Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary

More information

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions

More information

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management

More information

Icd 10 code for deep venous

Icd 10 code for deep venous Icd 10 code for deep venous thrombosis prophylaxis The Borg System is 100 % Icd 10 code for deep venous thrombosis prophylaxis PE. Pulmonary Embolus. F-10a Factor 10a Inhibitors. PH. Pulmonary. Hypertension.

More information

Direct Oral Anticoagulants

Direct Oral Anticoagulants Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish

More information

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical

More information

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation

Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist

More information

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published

More information

To prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban)

To prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban) To prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban) after hip or knee replacement surgery Always read the

More information

Obesity, renal failure, HIT: which anticoagulant to use?

Obesity, renal failure, HIT: which anticoagulant to use? Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

Clinical Guideline for Anticoagulation in VTE

Clinical Guideline for Anticoagulation in VTE Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that

More information

I. UNIFORM FORMULARY REVIEW PROCESS

I. UNIFORM FORMULARY REVIEW PROCESS DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented

More information

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US

More information

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet

More information

Treatment Options and How They Work

Treatment Options and How They Work Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the

More information

The Johns Hopkins Hospital Patient Information. How Do I Prevent Blood Clots? Venous Thromboembolism (VTE) Deep Vein Thrombosis (DVT)

The Johns Hopkins Hospital Patient Information. How Do I Prevent Blood Clots? Venous Thromboembolism (VTE) Deep Vein Thrombosis (DVT) Page 1 of 11 Venous Thromboembolism () What is a clot or Venous Thromboembolism ()? Blood clots are called Venous Thromboembolism (). There are 2 main types: is a clot in a deep vein, usually an arm or

More information

Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE

Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

New Oral Anticoagulant Drugs in the Prevention of DVT

New Oral Anticoagulant Drugs in the Prevention of DVT New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X

More information

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE

More information

ADVANCES IN ANTICOAGULATION

ADVANCES IN ANTICOAGULATION ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants

More information

Advances in Anticoagulation

Advances in Anticoagulation May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on

More information

Anticoagulation Task Force

Anticoagulation Task Force Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration

More information

Original Policy Date

Original Policy Date MP 5.01.15 Newer Oral Anticoagulants Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.

Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study. Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research

More information

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date: Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015

Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology

More information

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven

More information

Xarelto and plavix taken together.

Xarelto and plavix taken together. Toggle navigation Xarelto and plavix taken together. Integrilin (eptifibatide) helps to prevent platelets in your blood from sticking together and forming a blood clot. An unwanted blood clot can occur

More information

NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT

NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide guidance for the peri-operative management of patients who are receiving a newer direct oral anticoagulant (DOAC) and require an elective surgery/procedure.

More information

TSHP 2014 Annual Seminar 1

TSHP 2014 Annual Seminar 1 Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical

More information

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.

More information

Hot Topics: Transitions of Care

Hot Topics: Transitions of Care Our quarterly newsletter is a great way to stay up-to-date on emerging clinical information, medication safety issues, and Larkin s Hospital medication policies and procedures. Hot Topics: Transitions

More information

Acute Care: Understanding Direct Oral Anticoagulants (DOACs)

Acute Care: Understanding Direct Oral Anticoagulants (DOACs) Acute Care: Understanding Direct Oral Anticoagulants (DOACs) National Conference for Nurse Practitioners (NCNP) October 11, 2017 John Togami, PharmD, PhC Pharmacist Clinician - Outpatient Anticoagulation

More information

Southern Trust Anticoagulant Team

Southern Trust Anticoagulant Team CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute

More information

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape

More information

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional

More information

Low-Molecular-Weight Heparin

Low-Molecular-Weight Heparin Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:

More information

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic? Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer

More information

ANTICOAGULATION PROTOCOL

ANTICOAGULATION PROTOCOL ANTICOAGULATION PROTOCOL Clinical Guidance MARCH 2018 This is made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant this guidance for any other

More information

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin 1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,

More information

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,

More information

Slide 1. Slide 2. Slide 3. Outline of This Presentation

Slide 1. Slide 2. Slide 3. Outline of This Presentation Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients

More information

Abbreviated Class Update: Anticoagulants, oral and parenteral

Abbreviated Class Update: Anticoagulants, oral and parenteral Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

A Cascade of Updates: Hot Topics in Anticoagulation

A Cascade of Updates: Hot Topics in Anticoagulation A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate

More information

VTE Prevention After Hip or Knee Replacement

VTE Prevention After Hip or Knee Replacement This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of

More information

Anticoagulation

Anticoagulation 041218 Anticoagulation 2018 About This Presentation Strategic Vectors: Clinical Outcomes Patient Safety Physician Engagement Team: Dr. Joseph DeCristofaro Karin Ganetis, RN Dr. Stephen A. Vitkun Dr. Lisa

More information

Family Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008)

Family Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008) 1 Family Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008) Family Medicine Clinical Pharmacy Forum is a brief bi-monthly publication from the Family Medicine clinical pharmacists

More information